CBER 101 - Biologics License Application Process

More documents

Recommendations

Info

Filing Review • Review for completeness – RTF policy – CBER SOPP 8404 Refusal to File Guidance for Product License Applications and Establishment License Applications • Filing meeting • Filing letter • Communicate any significant deficiencies noted up to that time (but not a complete review) by day 74 C E B R
Refuse To File • A refusal to file (RTF) letter is issued when the submission has been deemed not sufficiently complete for a meaningful review • 21 CFR601.2(a), RTF Policy, SOPP 8404 • The Applicant may request that the submission be Filed Over Protest: SOPP 8404.1 C E B R
Page 1 and 2: The Biologics License Application P
Page 3 and 4: Drug development phases: Discovery
Page 5 and 6: CBER Regulatory Authority • BIOLO
Page 7 and 8: What is in a BLA? • Form FDA 356h
Page 9 and 10: BLA - Product/Manufacturing Informa
Page 11 and 12: International Harmonization Using t
Page 13 and 14: • MRP Managed Review Process - De
Page 15 and 16: The Review Committee CONSTITUTED TO
Page 17 and 18: Responsibilities Regulatory Project
Page 19 and 20: Before the BLA is Submitted • Pre
Page 21: SUBMISSION TRACKING NUMBER aaaaaa.b
Page 25 and 26: Complete Review • Substantive rev
Page 27 and 28: Discipline Reviews (DRs) • A DR l
Page 29 and 30: Action Decision • After a complet
Page 31 and 32: PDUFA Resubmissions • Guidance fo
Page 33 and 34: Dispute Resolution • Guidance for
Page 35 and 36: •SGRA Rules of the Road for Revie
Page 37 and 38: Good Review Management Principles
Page 39 and 40: Good Review Management Principles
Page 41: Good Review Management Principles

CBER 101 - Biologics License Application Process

Create successful ePaper yourself

Delete template?

Save as template?